Abstracts tagged "risk factors"

Abstract Number: 2509 • ACR Convergence 2025
Predicting future relapse with proteomics in ANCA-Associated Vasculitis
Evan Barnes¹, Nora Shepherd², Colebrooke Johnson¹, David O'Dea¹, Bohang Jiang³, Emily Hyle², Zachary Williams⁴, Zachary Wallace⁵ and Gary Reynolds⁶, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, ³MGH, Boston, MA, ⁴Massachusetts General Hospital, Nancy, KY, ⁵Massachusetts General Hospital, Newton, MA, ⁶Massachusetts General Hospital, Newcastle upon Tyne, United Kingdom
Background/Purpose: Outcomes for ANCA associated vasculitis (AAV) have been transformed in recent years with many patients achieving prolonged periods of remission. Guidelines advise continuing maintenance…
Abstract Number: 1832 • ACR Convergence 2025
Time-to-Event Analysis of Statin Use and Thrombotic Risk in Patients with Systemic Lupus Erythematosus: A Single-Center Retrospective Study
Christine Lenchur¹, Niurka Liranzo Tejera¹, Adal Abonamah¹, Takemichi Matsui¹, Emily Cosentino¹, Priscilla Abate Namnum², Olga Marushchak¹, Melissa Akselrad¹, Martin John³, Sophia Lutgen⁴, Celestine He⁵, Boluwatito Oladeinde³, Harleen Sidhu⁶, Emilia Bagiella⁵, Ian Wright⁵ and Chrisanna Dobrowolski⁵, ¹Mount Sinai Morningside/West Hospitals, Icahn School of Medicine at Mount Sinai, New York, NY, ²Mount Sinai Morningside/West Hospitals, Icahn School of Medicine at Mount Sinai, New York, ³Icahn School of Medicine at Mount Sinai, New York, ⁴Mount Sinai Morningside/West Hospitals, Icahn School of Medicine at Mount Sinai, New York City, NY, ⁵Icahn School of Medicine at Mount Sinai, New York, NY, ⁶Icahn School of Medicine at Mount Sinai/NYC H+H- Elmhurst, Queens, NY, Rego Park, NY
Background/Purpose: Patients with systemic lupus erythematosus (SLE) face elevated risk of thrombotic events (TEs) due to traditional cardiovascular factors and chronic inflammation. Statins may offer…
Abstract Number: 1467 • ACR Convergence 2025
Risk Factors Associated with Chronic Kidney Disease and End-Stage Kidney Disease in Patients with Newly Diagnosed Lupus Nephritis
Aakash V. Patel¹, Lingxiao Zhang², Hyon K. Choi³ and April Jorge⁴, ¹Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Massachusetts General Hospital, Boston, ³MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ⁴Massachusetts General Hospital, Boston, MA

Background/Purpose: Lupus nephritis (LN) affects over half of patients with systemic lupus erythematosus (SLE) and is associated with an increased risk for adverse kidney outcomes.…
Abstract Number: 0626 • ACR Convergence 2025
Evaluation of Novel Anti-ATP1A1 Autoantibodies by ELISA to Predict Cardiac Neonatal Lupus (Cardiac-NL)
Nalani Sachan¹, Philip Carlucci², Mala Masson³, Nicola Fraser¹, Peter Izmirly⁴, Camila Hernández-Blanco⁵, Robert Clancy⁶, Bettina Cuneo⁷ and Jill Buyon¹, ¹NYU Grossman School of Medicine, New York, NY, ²New York University School of Medicine, New York, NY, ³NYU Langone Medical Center- Division of Rheumatology, New York, NY, ⁴New York University Grossman School of Medicine, New York, NY, ⁵NYU Langone Health, New York, NY, ⁶Columbia University, New York, NY, ⁷University of Arizona College of Medicine, Tucson, AZ
Background/Purpose: For childbearing women with SLE and other autoimmune diseases, the nearly invariant association of cardiac-NL with maternal SSA/Ro52/60kD autoantibodies supports the necessity of these…
Abstract Number: 0392 • ACR Convergence 2025
Clinical Indicators of Methotrexate Response in Juvenile Idiopathic Arthritis (JIA) and JIA with Uveitis (JIA-U)
Abigale Jagger¹, Mara Becker², Susan Thompson³, Mekibib Altaye⁴, John Bohnsack⁵, Hermine Brunner⁶, Margaret Chang⁷, Ashley Cooper⁸, Stefanie Davidson⁹, Alexandra Duell⁶, Bharti Gangwani⁷, Carl Langefeld¹⁰, Melissa Lerman¹¹, Mindy Lo⁷, Serena Pastore¹², Mariia Pavlenko¹³, Sampath Prahalad¹⁴, Megan Quinlan-Waters¹⁵, Laura Ramsey¹⁶, Grant Schulert⁶, Gabriele Simonini¹⁷, Erin Stahl⁸, Gabriele Stocco¹⁸, Marc Sudman¹⁹, Andrea Taddio¹⁸, Virginia Miraldi Utz⁶, Rae Yeung²⁰ and Sheila Angeles-Han¹, ¹Cincinnati Children's Hospital, Cincinnati, OH, ²Duke University Medical Center/Duke Clinical Research Institute, Chapel Hill, NC, ³Cincinnati Children's Hospital Medical Center/Univ of Cincinnati College of Medicine, BLUE ASH, OH, ⁴Cincinnati Children's Hospital, Cincinnati, ⁵University of Utah, Salt Lake City, UT, ⁶Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁷Boston Children's Hospital, Boston, MA, ⁸Children's Mercy Kansas City, Kansas City, MO, ⁹University of Pennsylvania/CHOP, Philadelphia, PA, ¹⁰Wake Forest University School of Medicine, Winston Salem, NC, ¹¹Children's Hospital of Philadelphia, Philadelphia, PA, ¹²Institute of Child and Maternal Health - IRCCS "Burlo Garofolo", Trieste, Italy, ¹³Cincinnati Children`s Hospital Medical Center, Cincinnati, OH, ¹⁴Emory + Children's Pediatric Institute, Atlanta, GA, ¹⁵Cincinnati Children's Hospital Medical Center, CCHMC, ¹⁶Children's Mercy, Kansas City, MO, ¹⁷Rheumatology Unit, ERN-ReCONNET center, Meyer Children's Hospital IRCCS, Firenze, Firenze, Italy, ¹⁸Insitute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy, ¹⁹Cincinnati Children's Hospital Medical Center, Cincinnati, ²⁰The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
Background/Purpose: Patients with JIA are at high risk for development of chronic anterior uveitis (CAU), impacting 10-20% of this population. Although methotrexate (MTX) is the…
Abstract Number: 2496 • ACR Convergence 2025
Comparing Long-term Outcome Across Systemic Sclerosis Subgroups Using a Multi-Organ Disease Progression Score
Philip Yee¹, medha kanitkar², stefano rodolfi³, Voon H. Ong² and Christopher Denton⁴, ¹Division of Medicine, Centre for Rheumatology, University College London, London, England, United Kingdom, ²Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom, ³University College London, London, United Kingdom, ⁴University College London, UK, London, United Kingdom
Background/Purpose: Evaluating disease modification in systemic sclerosis (SSc) is challenging and requires long term studies. This is especially relevant to limited cutaneous (lc)SSc where severe…
Abstract Number: 1750 • ACR Convergence 2025
Urinary Proteomic Signature Identifies Rheumatoid Arthritis Patients at Risk for Interstitial Lung Disease
Jia Shi¹, Xueting Yuan², Yafang Deng³, Chen Yu⁴, Nan Jiang⁵, Zhengguang Guo⁶, Christian Lood⁷, Mengtao Li⁵, Wei Sun⁶, Qian Wang⁵ and Xinping Tian⁵, ¹University of Washington, Seattle, WA, ²Peking Union Medical College Hospital (CAMS), Beijing, China (People's Republic), ³Peking Union Medical College Hospital. Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, Beijing, China (People's Republic), ⁴Peking Union Medical College Hospital, Dong Cheng Qu, Beijing, China (People's Republic), ⁵Peking Union Medical College Hospital, Beijing, Beijing, China (People's Republic), ⁶Peking Union Medical College, Beijing, China (People's Republic), ⁷University of Washington, Division of Rheumatology, Seattle
Background/Purpose: Interstitial lung disease (ILD) is a serious pulmonary complication of rheumatoid arthritis (RA), contributing significantly to morbidity and mortality. Non-invasive tools for identifying ILD…
Abstract Number: 1336 • ACR Convergence 2025
Effectiveness of new initiators of tofacitinib and other biologic/targeted synthetic DMARDs in patients with rheumatoid arthritis
Katherine Liao¹, Chandrasekar Gopalakrishnan², Jinoos Yazdany³, Griffith Bell⁴, Suraj Mothi⁵, Genevieve Gauthier⁶, Arne Yndestad⁷ and Milena Gianfrancesco⁸, ¹Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital, Boston, MA, USA, Boston, MA, ²OM¹ Inc, Boston, MA, USA, Boston, ³UCSF, San Francisco, CA, ⁴Pfizer Inc, New York, NY, USA, Boston, MA, ⁵OM¹ Inc, Boston, MA, USA, Boston, MA, ⁶Pfizer Canada ULC, Kirkland, QC, Canada, Montreal, Canada, ⁷Pfizer Inc, Oslo, Norway, Oslo, Norway, ⁸Pfizer Inc, New York, NY, USA, New York, NY
Background/Purpose: Though the efficacy and safety profile of tofacitinib in RA has been established in prior trials, the effectiveness of tofacitinib in routine care settings…
Abstract Number: 0593 • ACR Convergence 2025
Genetic Risk Profiles Predict Clinical Heterogeneity in Systemic Lupus Erythematosus
Nina Oparina¹, Sarah Reid¹, Ahmne Sayadi¹, Maija-Leena Eloranta¹, Martina Frodlund², Karoline Lerang³, Andreas Jönsen⁴, Øyvind Molberg³, Solbritt Rantapää-Dahlqvist⁵, Anna Rudin⁶, Chrisopher Sjöwall⁷, Anders Bengtsson⁸, Lars Rönnblom¹ and Dag Leonard¹, ¹Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ²Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University, Linköping, Linkoping, Sweden, ³Department of Rheumatology, Oslo University Hospital, Oslo, Norway, ⁴Department of Clinical Sciences, Lund University,, Lund, Sweden, ⁵Department of Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, ⁶Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy of University of Gothenburg, Gothenburg, Sweden, ⁷Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University, Linköping, Sweden, ⁸Department of Clinical Sciences, Lund University, Lund, Sweden
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with diverse clinical manifestations. Genetic predisposition contributes significantly to its pathogenesis, and higher genetic load is…
Abstract Number: 0266 • ACR Convergence 2025
Chronic PPI Use Association with Development of Autoimmune Conditions: Retrospective Cohort Study
Nanuka Tsibadze¹, Irakli Tskhakaia¹, Rusudan Tskitishvili² and Fabian Rodriguez³, ¹Jefferson Health - Einstein, Philadelphia, PA, ²Virtua Health, Camden, NJ, ³Jefferson Health - Einstein, Philadelphia
Background/Purpose: Proton pump inhibitors (PPIs) are one of the most prescribed medications around the world. Recent research has increasingly identified adverse reactions in patients with…
Abstract Number: 2482 • ACR Convergence 2025
Characterizing Gastrointestinal Involvement in Systemic Sclerosis: Insights from the National Systemic sclerosis Progression INvestiGation (SPRING) Registry of the Italian Society of Rheumatology
Francesco Bonomi¹, Cosimo Bruni², Silvia Laura Bosello³, Fabio Cacciapaglia⁴, Corrado Campochiaro⁵, Roberto Caporali⁶, Veronica Codullo⁷, Maria Antonietta D'Agostino⁸, Lorenzo Dagna⁹, Rossella De Angelis¹⁰, Giacomo de Luca¹¹, Dilia Giuggioli¹², Serena Guiducci¹³, Florenzo Iannone¹⁴, Francesca Ingegnoli¹⁵, Carlomaurizio Montecucco⁷, Valeria Riccieri¹⁶, Clodoveo Ferri¹⁷, Marco Matucci-Cerinic¹⁸ and Silvia Bellando Randone¹⁹, ¹University Hospital Careggi, Florence, Florence, Toscana, Italy, ²University of Zurich, Zurich, Switzerland, ³Division of Rheumatology and Clinical Immunology - Catholic University of the Sacred Heart, Rome, Italy, Rome, Italy, ⁴Rheumatology Unit DiMePRe-J, University and AOU Policlinico of Bari & Department of Medicine LUM "G. De Gegnnaro" University, Casamassima (Bari) - Italy, Bari, Italy, ⁵IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milan, Milan, Italy, ⁶University of Milan and ASST Gaetano Pini-CTO, Milano, Italy, ⁷Policlinico San Matteo, Pavia, Pavia, Italy, ⁸Catholic University of the Sacred Heart, Rome, Rome, Italy, ⁹Ospedale San Raffaele, Milano, Italy, ¹⁰Polytechnic University of Marche, Ancona, Ancona, Italy, ¹¹Vita-Salute San Raffaele University. Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan, Italy, ¹²Rheumatology Unit, Department of Medical and Surgical Sciences for Children and Adults, University Hospital of Modena and Reggio Emilia School of Medicine, Italy., Modena, Emilia-Romagna, Italy, ¹³Division of Rheumatology, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, Florence, Italy, ¹⁴Rheumatology DiMePReJ, University of Bari, School of Medicine, Bari, Italy, Bari, Italy, ¹⁵Clinica Reumatologica, Dipartimento di Reumatologia e Scienze Mediche, ASST Gaetano Pini-CTO, Dipartimento di Scienze Cliniche e di Comunità, Dipartimento di Eccellenza ²⁰²³-²⁰²⁷, Università degli Studi di Milano, Milan, Italy, Milan, Italy, ¹⁶Sapienza University of Rome, Rheumatology Clinic, Rome, Italy, Roma, Italy, ¹⁷University of Modena and Reggio Emilia, Modena, Modena, Italy, ¹⁸University San Raffaele Milano, Milano, Milan, Italy, ¹⁹University of Florence, Florence, Italy
Background/Purpose: Gastrointestinal (GI) involvement affects over 80% of patients with systemic sclerosis (SSc), contributing significantly to morbidity and representing the third leading cause of disease-related…
Abstract Number: 1733 • ACR Convergence 2025
Risk factors for the development of immune checkpoint inhibitor-related adverse events, including rheumatology-related presentations
Adela Francis-Malave¹, Terri Laufer², Joshua Baker³, Kyra Sacksith⁴, Melissa Batson⁴ and Sokratis Apostolidis³, ¹University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, ²University of Pennsylvania, Bala Cynwyd, PA, ³University of Pennsylvania, Philadelphia, PA, ⁴University of Pennsylvania, Philadelphia
Background/Purpose: While immune-related adverse events (irAEs) are a commonly reported complication of immune checkpoint inhibitor (ICI) therapy, factors associated with their development remain poorly defined.…
Abstract Number: 1311 • ACR Convergence 2025
Decade-Based Trends in First Remission Among Rheumatoid Arthritis Patients: A Population-Based Study
Georges El Hasbani¹, Roslin George², Anne Shurtz¹, Cynthia Crowson³ and Elena myasoedova², ¹Mayo Clinic, Rochester, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Stewartvillle, MN
Background/Purpose: Early and aggressive treatment of rheumatoid arthritis (RA) has been linked to improved remission rates, but achieving early and sustained remission remains a challenging…
Abstract Number: 0884 • ACR Convergence 2025
Risk Score for Early Mortality to stratify for Intensive SSc Therapy
Ann-Christin Pecher¹, Boubaya Marouane², Oliver Distler³, Vanessa Smith⁴, Jeska de Vries-Bouwstra⁵, Radim Bečvář⁶, Gianluca Moroncini⁷, David Launay⁸, Yannick Allanore⁹, Maria De Santis¹⁰, Kamal Solanki¹¹, Carlomaurizio Montecucco¹², Luca Idolazzi¹³, Nihal Fathi¹⁴, Przemyslaw Kotyla¹⁵, Muriel Elhai¹⁶ and Jörg Henes¹⁷, ¹Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital Tübingen, Tübingen, Germany, ²Unit of Clinical Research, Paris Seine Saint Denis University, Bobigny, France, Paris, France, ³Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland, ⁴Ghent University Hospital, Gent, Belgium, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶Department of Internal Medicine, Charles University,, Prague, Czech Republic, ⁷Department of Internal Medicine, Marche University Hospital, Clinica Medica, Ancona, Italy, Ancona, Italy, ⁸Univ. Lille, Inserm, CHU Lille, U¹²⁸⁶ – INFINITE – Institute for Translational Research in Inflammation, Lille, France ; CHU Lille, Département de Médecine interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest, Méditerranée et Guadeloupe (CeRAINOM), Lille France, Lille, France, ⁹Department of Rheumatology, Université Paris Cité UFR de Médecine, Paris, France, ¹⁰Humanitas University, Pieve Emanuele, Italy, ¹¹Waikato Hospital, Hamilton, New Zealand, ¹²Department of Internal Medicine and Therapeutics, Università di Pavia, Pavia, Italy, Pavia, Italy, ¹³Rheumatology Section, Department of Medicine, University of Verona, Verona, Italy, Verona, Italy, ¹⁴Department of Rheumatology ,Rehabilitation & physical medicine, Assiut University Hospital, Assiut, Egypt, Assiut, Egypt, ¹⁵Department of Internal Medicine, Rheumatology and Clinical Immunology, Medical University of Silesia, Katowice, Poland, ¹⁶University Hospital zurich, Zürich, Switzerland, ¹⁷Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital Tübingen, Tuebingen, Germany
Background/Purpose: Systemic sclerosis (SSc) is a rare disease that often leads to severe complications and premature mortality. Recent advancements in the field have led to…
Abstract Number: 0205 • ACR Convergence 2025
Implementation of the Varicella Zoster virus vaccine and its Real-World effectiveness
Laura Mas Sanchez¹, ELENA GRAU GARCIA², Carlos Valera Ribera³, Pablo Muñoz-Martínez⁴, Daniel Ramos Castro⁵, Alba Maria Torrat Noves⁶, Belen Villanueva Manes⁷, Iago Alcántara Álvarez⁸, Miguel Simeo Vinaixa⁹, Andres Perez Hurtado¹⁰ and José Andrés Román Ivorra¹¹, ¹Hospital Universitari i Politecnic La Fe, València, Spain, ²HUP La Fe, Valencia, Comunidad Valenciana, Spain, ³Hospital Universitario Doctor Peset, València, Spain, ⁴Hospital Universitario y Politécnico La Fe, Sagunto, Spain, ⁵Hospital Universitari i Politecnic La Fe, Valencia, Spain, ⁶Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Spain, ⁷Hospital La Fe, València, Spain, ⁸Hospital Universitari i Politénic La Fe, València, Spain, ⁹Rheumatology Department. HUP La Fe, Valencia, Spain, ¹⁰Hospital Universitario y Politècnico La Fe, València, Comunidad Valenciana, Spain, ¹¹Hospital Universitari i Politècnic La Fe, Valencia, Spain
Background/Purpose: In 2023, Spain approved the inactivated varicella zoster virus (VZV) vaccine in individuals over 50 years of age with immunosuppressive conditions, including rheumatology patients…

1
2
3
…
28
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].